Sort
82,697 grants matching “vaccine development”
A vaccine design to induce protective B and T cell immunity against hepatitis C virus
$2,498,468Steven Foung · Stanford University · U19 · FY2022 · AI
University of Puerto Rico Clinical Trials Unit
$2,497,560Carmen D Zorrilla · University Of Puerto Rico Med Sciences · U01 · FY2011 · AI
Environmental/genetic Risk Factors and Pathogenesis of Autoimmune Disease
$2,497,417Frederick Miller · National Institute Of Environmental Health Sciences · ZIA · FY2020 · ES
B Cell Biology
$2,497,322Susan Pierce · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Microbiome Discovery and Mechanisms to Combat Antibiotic Resistance at Mucosal Surfaces
$2,497,111Robert A Britton · Baylor College Of Medicine · U19 · FY2024 · AI
NIH TETRAMER CORE FACILITY (INFECTIOUS DISEASES OTHER THAN HIV/AIDS)
$2,496,777John Altman · Emory University · N01 · FY2020 · AI
Positioning Mason's Regional Biocontainment Laboratory for Effective Pandemic Preparedness
$2,495,244Farhang Alem · George Mason University · UC7 · FY2023 · AI
RFA-IP-22-004, Evaluating respiratory virus vaccine effectiveness in a large, diverse healthcare system
$2,495,017Richard K Zimmerman · University Of Pittsburgh At Pittsburgh · U01 · FY2022 · IP
Programming Long-lasting Immunity to Coronaviruses (PLUTO)
$2,494,973Viviana A Simon · Icahn School Of Medicine At Mount Sinai · P01 · FY2025 · AI
Programming Long-lasting Immunity to Coronaviruses (PLUTO)
$2,494,973Viviana A Simon · Icahn School Of Medicine At Mount Sinai · P01 · FY2024 · AI
UCLA AIDS Prevention and Treatment Clinical Trials Unit
$2,494,558Judith S. Currier · University Of California Los Angeles · UM1 · FY2013 · AI
Adjuvant Development in the context of a vaccine to protect against tuberculosis
$2,494,333Vaxine Pty Ltd · N01 · FY2018 · AI
Experimental Therapy for Brain Tumors
$2,494,255David M. Ashley · Duke University · P01 · FY2022 · CA
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplication
$2,492,623Ian Matthias Sanne · Wits Health Consortium (Pty), Ltd · UM1 · FY2023 · AI
Task X15: Evaluation of Ebolavirus and Other Filovirus Vaccines in a Novel Animal Model
$2,492,268Randi Hornback · Battelle Centers/Pub Hlth Res & Evaluatn · N01 · FY2016 · AI
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)
$2,492,267David S Stephens · Emory University · UM1 · FY2020 · AI
Viral Respiratory Pathogens Research Unit
$2,491,638Robert B Couch · Baylor College Of Medicine · N01 · FY2009 · AI
HSV-1 Amplicon Vectors for HIV Vaccine Delivery
$2,491,559University Of Rochester · P01 · FY2004 · AI
Expansion of an established breeding SPF Program at CPRC
$2,491,442Carlos A Sariol · University Of Puerto Rico Med Sciences · C06 · FY2024 · OD
Fred Hutchinson Cancer Research Center Lung SPORE
$2,491,191A. McGarry Houghton · Fred Hutchinson Cancer Research Center · P50 · FY2019 · CA
Emerging Infectious Diseases Research Centers Coordination Center (EIDRC CC)
$2,490,957Donald Brambilla · Research Triangle Institute · U01 · FY2021 · AI
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response
$2,490,943Jamey P Weichert · University Of Wisconsin-Madison · P01 · FY2020 · CA
THE COMPLETION OF CMC DEVELOPMENT AND PRODUCTION OF PILOT-SCALE CGMP LOSTS OF VLPM01, A MALARIA VACCINE CANDIDATE
$2,490,865Vlp Therapeutics, Inc. · · FY2016 · Department of Defense
Translational Immunology Research and Accelerated [vaccine] Development (TRIAD)
$2,490,625Anne Searls De Groot · University Of Rhode Island · U19 · FY2012 · AI
Development of Vaccines to Prevent Tuberculosis
$2,490,549Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI